Altimmune

Youtube Subscribe

Open: 4.91 Close: 4.99 Change: 0.09

The unbelievably easy way to evaluate Altimmune Company Inc: Use an AI.

This document will help you to evaluate Altimmune without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Altimmune are: Altimmune, May, participate, upcoming, investor, conference, Tuesday, and the …

Concept Map

Semantic Network

Stock Summary

Altimmune, Inc. focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, is in Phase 2 trial for obesity. It is also developing HepTcell, an immunother.

Today's Summary

Altimmune (NASDAQ: ALT) stock is losing value on Tuesday after the company released results from a clinical trial. Altimmune is constantly working on weight-loss programs similar to Novo Nordisks Wegovy.

Today's News

Altimmune to participate at two upcoming investor conferences. JMP Securities Life Sciences Conference in New York, NY Tuesday, May 16, 2023 Fireside chat at 9:00 am Eastern Time. Piper Sandler Spring Biopharma Symposium in Boston, MA Thursday, May 18, 20 23 One-on-one meetings only. Altimmune (NASDAQ: ALT) stock is losing value on Tuesday after the company released results from a clinical trial. Altimmune is constantly working on weight-loss programs similar to Novo Nordisks Wegovy. Altimmune stock has a Z-Score of 97.14. Comparative valuation techniques use various fundamental indicators to help in determining Altimmunes value. Profitability drivers are factors that can directly affect your investment outlook on Altimmune. Profitability progress is the general direction of Altimmunes change in net profit over the period of time. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Altimmune, Inc. (NASDAQ:ALT) Shares Bought by Toronto Dominion Bank. Altimmune to Participate at Two Upcoming Investor Conferences - May 8, 2023 5/8/2023 Altimmune, Inc. altimmune to participate at two upcoming investor conferences. Altimmune is a clinical-stage biopharmaceutical company focused on the developmentof novel peptide-based therapeutics for the treatment of obesityand liver diseases. UAB will test a COVID-19 vaccine candidate created by Altimmune.

Stock Profile

"Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland."

Keywords

How much time have you spent trying to decide whether investing in Altimmune? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Altimmune are: Altimmune, May, participate, upcoming, investor, conference, Tuesday, and the most common words in the summary are: altimmune, inc, stock, news, company, alt, market, . One of the sentences in the summary was: Altimmune (NASDAQ: ALT) stock is losing value on Tuesday after the company released results from a clinical trial. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #altimmune #inc #stock #news #company #alt #market.

Read more →

Youtube Subscribe

---